Huayu Hu1,2, Mengke Zhang3, Yuan Liu3, Xi-Ru Li2, Gang Liu4, Zhili Wang3. 1. School of Medicine, Nankai University, Tianjin, China. 2. Department of General Surgery, Chinese People's Liberation Army General Hospital, Beijing, China. 3. Department of Ultrasound, Chinese People's Liberation Army General Hospital, Beijing, China. 4. Department of Radiology, Chinese People's Liberation Army General Hospital, Beijing, China.
Abstract
BACKGROUND: Mammary hamartomas were mostly benign tumors with rare rate of recurrence and malignant transformation. Ultrasound (US)-guided vacuum-assisted breast biopsy (VABB) has been reported sufficiently safe in treating many breast benign tumors but remained undefined in mammary hamartoma for its usual underdiagnosis in US. Thus, this study aims to evaluate the efficiency of US-guided VABB in treating mammary hamartomas. METHODS: From May 2015 to March 2019, 3,388 lesions of 2,534 patients underwent percutaneous US-guided VABB, among which 31 mammary hamartomas proved by pathology were included in this study. Patients were followed up by US three, six and twelve months later, then at 1-year intervals. Lesions were classified to analyze the possible factors associated with excision rate, bleeding volume and complications. RESULTS: Of the 31 patients, recurrence was seen in 1 case in 1 year after the procedure and complete excision rate was 96.8% (30/31). The bleeding volume ranged from 1 to 15 mL (mean number ± standard deviation, 6.5±3.4 mL) and significant statistical differences were detected in patient age and the largest diameter of lesions. The main complications included pain (22.6%), hematomas (9.7%) and ecchymosis (3.2%). CONCLUSIONS: US-guided VABB ensures an outstanding complete excision rate and provides an alternative solution to treat mammary hamartomas. 2020 Gland Surgery. All rights reserved.
BACKGROUND: Mammary hamartomas were mostly benign tumors with rare rate of recurrence and malignant transformation. Ultrasound (US)-guided vacuum-assisted breast biopsy (VABB) has been reported sufficiently safe in treating many breast benign tumors but remained undefined in mammary hamartoma for its usual underdiagnosis in US. Thus, this study aims to evaluate the efficiency of US-guided VABB in treating mammary hamartomas. METHODS: From May 2015 to March 2019, 3,388 lesions of 2,534 patients underwent percutaneous US-guided VABB, among which 31 mammary hamartomas proved by pathology were included in this study. Patients were followed up by US three, six and twelve months later, then at 1-year intervals. Lesions were classified to analyze the possible factors associated with excision rate, bleeding volume and complications. RESULTS: Of the 31 patients, recurrence was seen in 1 case in 1 year after the procedure and complete excision rate was 96.8% (30/31). The bleeding volume ranged from 1 to 15 mL (mean number ± standard deviation, 6.5±3.4 mL) and significant statistical differences were detected in patient age and the largest diameter of lesions. The main complications included pain (22.6%), hematomas (9.7%) and ecchymosis (3.2%). CONCLUSIONS: US-guided VABB ensures an outstanding complete excision rate and provides an alternative solution to treat mammary hamartomas. 2020 Gland Surgery. All rights reserved.